Nkarta, Inc. (NASDAQ:NKTX) Shares Purchased by Wasatch Advisors LP

Wasatch Advisors LP increased its stake in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 37.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,520,909 shares of the company's stock after purchasing an additional 686,229 shares during the quarter. Wasatch Advisors LP owned approximately 3.57% of Nkarta worth $6,277,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Affinity Asset Advisors LLC raised its stake in shares of Nkarta by 23.1% during the 4th quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company's stock worth $1,992,000 after acquiring an additional 150,000 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Nkarta during the fourth quarter worth about $183,000. Barclays PLC increased its holdings in shares of Nkarta by 16.5% during the fourth quarter. Barclays PLC now owns 270,857 shares of the company's stock valued at $674,000 after acquiring an additional 38,291 shares in the last quarter. Invesco Ltd. acquired a new position in shares of Nkarta during the fourth quarter valued at about $30,000. Finally, Aristides Capital LLC acquired a new stake in Nkarta in the 4th quarter worth approximately $210,000. Institutional investors own 80.54% of the company's stock.

Wall Street Analysts Forecast Growth

NKTX has been the topic of a number of recent analyst reports. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Nkarta in a research note on Thursday, March 27th. Stifel Nicolaus cut their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Nkarta in a research report on Wednesday, April 9th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Nkarta presently has a consensus rating of "Buy" and an average target price of $14.86.

Nkarta Price Performance

NASDAQ:NKTX traded up $0.24 during trading hours on Tuesday, reaching $2.09. The company had a trading volume of 1,028,899 shares, compared to its average volume of 1,094,265. Nkarta, Inc. has a 1-year low of $1.31 and a 1-year high of $8.33. The business's 50 day moving average price is $1.77 and its 200-day moving average price is $2.43. The firm has a market cap of $147.95 million, a PE ratio of -1.11 and a beta of 0.83.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06. On average, analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.